Report Detail

Pharma & Healthcare Global Anaplastic Lymphoma Kinase Inhibitors Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024

  • RnM3816616
  • |
  • 15 October, 2019
  • |
  • Global
  • |
  • 107 Pages
  • |
  • GIR (Global Info Research)
  • |
  • Pharma & Healthcare

Scope of the Report:
The worldwide market for Anaplastic Lymphoma Kinase Inhibitors is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Anaplastic Lymphoma Kinase Inhibitors in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Market Segment by Manufacturers, this report covers
Pfizer, Inc.
Takeda Pharmaceutical Co., Ltd.
Helsinn Therapeutics
Crtierium, Inc.
Betta Pharmaceutcials Co., Ltd.
F.Hoffman-La Roche Ltd.
Tesaro, Inc.
Oncoethix GmbH
Novartis AG.
Xcovery Holding Company, LLC

Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
Crizotinib
Ceritinib
Alectinib Hydrochloride

Market Segment by Applications, can be divided into
NSCLC
Breast Cancer
Colorectal Cancer
Neuroblastoma
Ovarian Cancer
Others

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Anaplastic Lymphoma Kinase Inhibitors product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Anaplastic Lymphoma Kinase Inhibitors, with price, sales, revenue and global market share of Anaplastic Lymphoma Kinase Inhibitors in 2017 and 2018.
Chapter 3, the Anaplastic Lymphoma Kinase Inhibitors competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Anaplastic Lymphoma Kinase Inhibitors breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Anaplastic Lymphoma Kinase Inhibitors market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Anaplastic Lymphoma Kinase Inhibitors sales channel, distributors, customers, research findings and conclusion, appendix and data source.


Table of Contents

    1 Market Overview

    • 1.1 Anaplastic Lymphoma Kinase Inhibitors Introduction
    • 1.2 Market Analysis by Type
      • 1.2.1 Crizotinib
      • 1.2.2 Ceritinib
      • 1.2.3 Alectinib Hydrochloride
    • 1.3 Market Analysis by Applications
      • 1.3.1 NSCLC
      • 1.3.2 Breast Cancer
      • 1.3.3 Colorectal Cancer
      • 1.3.4 Neuroblastoma
      • 1.3.5 Ovarian Cancer
      • 1.3.6 Others
    • 1.4 Market Analysis by Regions
      • 1.4.1 North America (United States, Canada and Mexico)
        • 1.4.1.1 United States Market States and Outlook (2014-2024)
        • 1.4.1.2 Canada Market States and Outlook (2014-2024)
        • 1.4.1.3 Mexico Market States and Outlook (2014-2024)
      • 1.4.2 Europe (Germany, France, UK, Russia and Italy)
        • 1.4.2.1 Germany Market States and Outlook (2014-2024)
        • 1.4.2.2 France Market States and Outlook (2014-2024)
        • 1.4.2.3 UK Market States and Outlook (2014-2024)
        • 1.4.2.4 Russia Market States and Outlook (2014-2024)
        • 1.4.2.5 Italy Market States and Outlook (2014-2024)
      • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
        • 1.4.3.1 China Market States and Outlook (2014-2024)
        • 1.4.3.2 Japan Market States and Outlook (2014-2024)
        • 1.4.3.3 Korea Market States and Outlook (2014-2024)
        • 1.4.3.4 India Market States and Outlook (2014-2024)
        • 1.4.3.5 Southeast Asia Market States and Outlook (2014-2024)
      • 1.4.4 South America, Middle East and Africa
        • 1.4.4.1 Brazil Market States and Outlook (2014-2024)
        • 1.4.4.2 Egypt Market States and Outlook (2014-2024)
        • 1.4.4.3 Saudi Arabia Market States and Outlook (2014-2024)
        • 1.4.4.4 South Africa Market States and Outlook (2014-2024)
        • 1.4.4.5 Turkey Market States and Outlook (2014-2024)
    • 1.5 Market Dynamics
      • 1.5.1 Market Opportunities
      • 1.5.2 Market Risk
      • 1.5.3 Market Driving Force

    2 Manufacturers Profiles

    • 2.1 Pfizer, Inc.
      • 2.1.1 Business Overview
      • 2.1.2 Anaplastic Lymphoma Kinase Inhibitors Type and Applications
        • 2.1.2.1 Product A
        • 2.1.2.2 Product B
      • 2.1.3 Pfizer, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.2 Takeda Pharmaceutical Co., Ltd.
      • 2.2.1 Business Overview
      • 2.2.2 Anaplastic Lymphoma Kinase Inhibitors Type and Applications
        • 2.2.2.1 Product A
        • 2.2.2.2 Product B
      • 2.2.3 Takeda Pharmaceutical Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.3 Helsinn Therapeutics
      • 2.3.1 Business Overview
      • 2.3.2 Anaplastic Lymphoma Kinase Inhibitors Type and Applications
        • 2.3.2.1 Product A
        • 2.3.2.2 Product B
      • 2.3.3 Helsinn Therapeutics Anaplastic Lymphoma Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.4 Crtierium, Inc.
      • 2.4.1 Business Overview
      • 2.4.2 Anaplastic Lymphoma Kinase Inhibitors Type and Applications
        • 2.4.2.1 Product A
        • 2.4.2.2 Product B
      • 2.4.3 Crtierium, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.5 Betta Pharmaceutcials Co., Ltd.
      • 2.5.1 Business Overview
      • 2.5.2 Anaplastic Lymphoma Kinase Inhibitors Type and Applications
        • 2.5.2.1 Product A
        • 2.5.2.2 Product B
      • 2.5.3 Betta Pharmaceutcials Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.6 F.Hoffman-La Roche Ltd.
      • 2.6.1 Business Overview
      • 2.6.2 Anaplastic Lymphoma Kinase Inhibitors Type and Applications
        • 2.6.2.1 Product A
        • 2.6.2.2 Product B
      • 2.6.3 F.Hoffman-La Roche Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.7 Tesaro, Inc.
      • 2.7.1 Business Overview
      • 2.7.2 Anaplastic Lymphoma Kinase Inhibitors Type and Applications
        • 2.7.2.1 Product A
        • 2.7.2.2 Product B
      • 2.7.3 Tesaro, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.8 Oncoethix GmbH
      • 2.8.1 Business Overview
      • 2.8.2 Anaplastic Lymphoma Kinase Inhibitors Type and Applications
        • 2.8.2.1 Product A
        • 2.8.2.2 Product B
      • 2.8.3 Oncoethix GmbH Anaplastic Lymphoma Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.9 Novartis AG.
      • 2.9.1 Business Overview
      • 2.9.2 Anaplastic Lymphoma Kinase Inhibitors Type and Applications
        • 2.9.2.1 Product A
        • 2.9.2.2 Product B
      • 2.9.3 Novartis AG. Anaplastic Lymphoma Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.10 Xcovery Holding Company, LLC
      • 2.10.1 Business Overview
      • 2.10.2 Anaplastic Lymphoma Kinase Inhibitors Type and Applications
        • 2.10.2.1 Product A
        • 2.10.2.2 Product B
      • 2.10.3 Xcovery Holding Company, LLC Anaplastic Lymphoma Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)

    3 Global Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue, Market Share and Competition by Manufacturer (2017-2018)

    • 3.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales and Market Share by Manufacturer (2017-2018)
    • 3.2 Global Anaplastic Lymphoma Kinase Inhibitors Revenue and Market Share by Manufacturer (2017-2018)
    • 3.3 Market Concentration Rate
      • 3.3.1 Top 3 Anaplastic Lymphoma Kinase Inhibitors Manufacturer Market Share in 2018
      • 3.3.2 Top 6 Anaplastic Lymphoma Kinase Inhibitors Manufacturer Market Share in 2018
    • 3.4 Market Competition Trend

    4 Global Anaplastic Lymphoma Kinase Inhibitors Market Analysis by Regions

    • 4.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Market Share by Regions
      • 4.1.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales and Market Share by Regions (2014-2019)
      • 4.1.2 Global Anaplastic Lymphoma Kinase Inhibitors Revenue and Market Share by Regions (2014-2019)
    • 4.2 North America Anaplastic Lymphoma Kinase Inhibitors Sales and Growth Rate (2014-2019)
    • 4.3 Europe Anaplastic Lymphoma Kinase Inhibitors Sales and Growth Rate (2014-2019)
    • 4.4 Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales and Growth Rate (2014-2019)
    • 4.5 South America Anaplastic Lymphoma Kinase Inhibitors Sales and Growth Rate (2014-2019)
    • 4.6 Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales and Growth Rate (2014-2019)

    5 North America Anaplastic Lymphoma Kinase Inhibitors by Country

    • 5.1 North America Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Market Share by Country
      • 5.1.1 North America Anaplastic Lymphoma Kinase Inhibitors Sales and Market Share by Country (2014-2019)
      • 5.1.2 North America Anaplastic Lymphoma Kinase Inhibitors Revenue and Market Share by Country (2014-2019)
    • 5.2 United States Anaplastic Lymphoma Kinase Inhibitors Sales and Growth Rate (2014-2019)
    • 5.3 Canada Anaplastic Lymphoma Kinase Inhibitors Sales and Growth Rate (2014-2019)
    • 5.4 Mexico Anaplastic Lymphoma Kinase Inhibitors Sales and Growth Rate (2014-2019)

    6 Europe Anaplastic Lymphoma Kinase Inhibitors by Country

    • 6.1 Europe Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Market Share by Country
      • 6.1.1 Europe Anaplastic Lymphoma Kinase Inhibitors Sales and Market Share by Country (2014-2019)
      • 6.1.2 Europe Anaplastic Lymphoma Kinase Inhibitors Revenue and Market Share by Country (2014-2019)
    • 6.2 Germany Anaplastic Lymphoma Kinase Inhibitors Sales and Growth Rate (2014-2019)
    • 6.3 UK Anaplastic Lymphoma Kinase Inhibitors Sales and Growth Rate (2014-2019)
    • 6.4 France Anaplastic Lymphoma Kinase Inhibitors Sales and Growth Rate (2014-2019)
    • 6.5 Russia Anaplastic Lymphoma Kinase Inhibitors Sales and Growth Rate (2014-2019)
    • 6.6 Italy Anaplastic Lymphoma Kinase Inhibitors Sales and Growth Rate (2014-2019)

    7 Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors by Country

    • 7.1 Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Market Share by Country
      • 7.1.1 Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales and Market Share by Country (2014-2019)
      • 7.1.2 Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Revenue and Market Share by Country (2014-2019)
    • 7.2 China Anaplastic Lymphoma Kinase Inhibitors Sales and Growth Rate (2014-2019)
    • 7.3 Japan Anaplastic Lymphoma Kinase Inhibitors Sales and Growth Rate (2014-2019)
    • 7.4 Korea Anaplastic Lymphoma Kinase Inhibitors Sales and Growth Rate (2014-2019)
    • 7.5 India Anaplastic Lymphoma Kinase Inhibitors Sales and Growth Rate (2014-2019)
    • 7.6 Southeast Asia Anaplastic Lymphoma Kinase Inhibitors Sales and Growth Rate (2014-2019)

    8 South America Anaplastic Lymphoma Kinase Inhibitors by Country

    • 8.1 South America Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Market Share by Country
      • 8.1.1 South America Anaplastic Lymphoma Kinase Inhibitors Sales and Market Share by Country (2014-2019)
      • 8.1.2 South America Anaplastic Lymphoma Kinase Inhibitors Revenue and Market Share by Country (2014-2019)
    • 8.2 Brazil Anaplastic Lymphoma Kinase Inhibitors Sales and Growth Rate (2014-2019)
    • 8.3 Argentina Anaplastic Lymphoma Kinase Inhibitors Sales and Growth Rate (2014-2019)
    • 8.4 Colombia Anaplastic Lymphoma Kinase Inhibitors Sales and Growth Rate (2014-2019)

    9 Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors by Countries

    • 9.1 Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Market Share by Country
      • 9.1.1 Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales and Market Share by Country (2014-2019)
      • 9.1.2 Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Revenue and Market Share by Country (2014-2019)
    • 9.2 Saudi Arabia Anaplastic Lymphoma Kinase Inhibitors Sales and Growth Rate (2014-2019)
    • 9.3 Turkey Anaplastic Lymphoma Kinase Inhibitors Sales and Growth Rate (2014-2019)
    • 9.4 Egypt Anaplastic Lymphoma Kinase Inhibitors Sales and Growth Rate (2014-2019)
    • 9.5 Nigeria Anaplastic Lymphoma Kinase Inhibitors Sales and Growth Rate (2014-2019)
    • 9.6 South Africa Anaplastic Lymphoma Kinase Inhibitors Sales and Growth Rate (2014-2019)

    10 Global Anaplastic Lymphoma Kinase Inhibitors Market Segment by Type

    • 10.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Market Share by Type (2014-2019)
      • 10.1.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales and Market Share by Type (2014-2019)
      • 10.1.2 Global Anaplastic Lymphoma Kinase Inhibitors Revenue and Market Share by Type (2014-2019)
    • 10.2 Crizotinib Sales Growth and Price
      • 10.2.1 Global Crizotinib Sales Growth (2014-2019)
      • 10.2.2 Global Crizotinib Price (2014-2019)
    • 10.3 Ceritinib Sales Growth and Price
      • 10.3.1 Global Ceritinib Sales Growth (2014-2019)
      • 10.3.2 Global Ceritinib Price (2014-2019)
    • 10.4 Alectinib Hydrochloride Sales Growth and Price
      • 10.4.1 Global Alectinib Hydrochloride Sales Growth (2014-2019)
      • 10.4.2 Global Alectinib Hydrochloride Price (2014-2019)

    11 Global Anaplastic Lymphoma Kinase Inhibitors Market Segment by Application

    • 11.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application (2014-2019)
    • 11.2 NSCLC Sales Growth (2014-2019)
    • 11.3 Breast Cancer Sales Growth (2014-2019)
    • 11.4 Colorectal Cancer Sales Growth (2014-2019)
    • 11.5 Neuroblastoma Sales Growth (2014-2019)
    • 11.6 Ovarian Cancer Sales Growth (2014-2019)
    • 11.7 Others Sales Growth (2014-2019)

    12 Anaplastic Lymphoma Kinase Inhibitors Market Forecast (2019-2024)

    • 12.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Growth Rate (2019-2024)
    • 12.2 Anaplastic Lymphoma Kinase Inhibitors Market Forecast by Regions (2019-2024)
      • 12.2.1 North America Anaplastic Lymphoma Kinase Inhibitors Market Forecast (2019-2024)
      • 12.2.2 Europe Anaplastic Lymphoma Kinase Inhibitors Market Forecast (2019-2024)
      • 12.2.3 Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Market Forecast (2019-2024)
      • 12.2.4 South America Anaplastic Lymphoma Kinase Inhibitors Market Forecast (2019-2024)
      • 12.2.5 Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Market Forecast (2019-2024)
    • 12.3 Anaplastic Lymphoma Kinase Inhibitors Market Forecast by Type (2019-2024)
      • 12.3.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales Forecast by Type (2019-2024)
      • 12.3.2 Global Anaplastic Lymphoma Kinase Inhibitors Market Share Forecast by Type (2019-2024)
    • 12.4 Anaplastic Lymphoma Kinase Inhibitors Market Forecast by Application (2019-2024)
      • 12.4.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales Forecast by Application (2019-2024)
      • 12.4.2 Global Anaplastic Lymphoma Kinase Inhibitors Market Share Forecast by Application (2019-2024)

    13 Sales Channel, Distributors, Traders and Dealers

    • 13.1 Sales Channel
      • 13.1.1 Direct Marketing
      • 13.1.2 Indirect Marketing
      • 13.1.3 Marketing Channel Future Trend
    • 13.2 Distributors, Traders and Dealers

    14 Research Findings and Conclusion

      15 Appendix

      • 15.1 Methodology

      Summary:
      Get latest Market Research Reports on Anaplastic Lymphoma Kinase Inhibitors. Industry analysis & Market Report on Anaplastic Lymphoma Kinase Inhibitors is a syndicated market report, published as Global Anaplastic Lymphoma Kinase Inhibitors Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024. It is complete Research Study and Industry Analysis of Anaplastic Lymphoma Kinase Inhibitors market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,480.00
      $5,220.00
      $6,960.00
      2,787.48
      4,181.22
      5,574.96
      3,250.32
      4,875.48
      6,500.64
      548,065.20
      822,097.80
      1,096,130.40
      290,197.20
      435,295.80
      580,394.40
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report